Watch ALNY. Know when insiders buy.
One email the day a filing lands. Free.
ALNY
ALNYLAM PHARMACEUTICALS, INC.
266.11
+1.61 +0.61%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
52
WATCH · shorts 52
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
2 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $35.6BP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME $733.1MNET CASH $1B52W 205.48 – 491.22SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.3B | +66.9% | 76.9% | $231.4M | $164.5M | — | 1.21 | — | — | — | Jul 30 |
| Q1 2026 · Mar 31 | — | — | — | — | $206M | — | — | — | — | — | Jul 30 |
| Q4 2025 · Dec 31derived | $1.1B | +84.9% | 75.6% | $131.7M | $111.5M | — | 0.82 | $163.6M | $23.3M | $140.3M | Feb 12 |
| Q3 2025 · Sep 30 | $1.2B | +149.3% | 84.2% | $368M | $251.1M | — | 1.84 | $351M | $12.1M | $338.9M | Feb 12 |
| Q2 2025 · Jun 30 | $773.7M | +17.3% | 81.6% | −$16.2M | −$72.2M | — | -0.55 | $127.8M | $14.3M | $113.5M | Jul 30 |
| Q1 2025 · Mar 31 | $594.2M | +20.2% | 88.2% | $18.1M | −$18.3M | — | -0.14 | −$118.3M | $9M | −$127.3M | Jul 30 |
| Q4 2024 · Dec 31derived | $593.2M | +34.9% | 82.7% | −$105.2M | −$83.8M | — | -0.65 | −$94.7M | $9.1M | −$103.8M | Feb 12 |
| Q3 2024 · Sep 30 | $500.9M | −33.3% | 83.6% | −$76.9M | −$111.6M | −175.5% | -0.87 | $43.7M | $4.2M | $39.5M | Oct 30 |
| Q2 2024 · Jun 30 | $659.8M | — | 89.8% | $48.6M | −$16.9M | — | -0.13 | $124.2M | $8M | $116.1M | Oct 30 |
| Q1 2024 · Mar 31 | $494.3M | — | 89.0% | −$43.4M | −$65.9M | — | -0.52 | −$81.5M | $13M | −$94.5M | Oct 30 |
| Q4 2023 · Dec 31derived | $439.7M | — | 83.6% | −$116.4M | −$137.9M | — | -1.09 | −$29.8M | $15.3M | −$45.1M | Feb 12 |
| Q3 2023 · Sep 30 | $750.5M | — | 89.4% | $213.9M | $147.8M | — | 1.15 | $359.4M | $17.1M | $342.3M | Oct 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $3.7B | 81.8% | $501.6M | $313.7M | 8.4% | 2.33 | $524.1M | $58.7M | $465.4M | — | — |
| FY2024 · to Dec 31 | $2.2B | 86.4% | −$176.9M | −$278.2M | -12.4% | -2.18 | −$8.3M | $34.3M | −$42.6M | — | — |
| FY2023 · to Dec 31 | $1.8B | 85.3% | −$282.2M | −$440.2M | -24.1% | -3.52 | $104.2M | $62.2M | $41.9M | — | — |
| FY2022 · to Dec 31 | $1B | 86.5% | −$785.1M | −$1.1B | -109.0% | -9.30 | −$541.3M | $72.1M | −$613.3M | — | — |
| FY2021 · to Dec 31 | $844.3M | 86.4% | −$708.7M | −$852.8M | -101.0% | -7.20 | −$641.7M | $76.4M | −$718.1M | — | — |
| FY2020 · to Dec 31 | $492.9M | 84.9% | −$828.4M | −$858.3M | -174.1% | -7.46 | −$615M | $70.4M | −$685.3M | — | — |
Every number comes from ALNYLAM PHARMACEUTICALS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.